Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs
- 1 May 2009
- journal article
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 20 (5), 339-345
- https://doi.org/10.1258/ijsa.2008.008361
Abstract
This study investigated whether serious adverse events (SAEs) during antituberculosis therapy occur more frequently in HIV co-infected patients in a South African population. A retrospective analysis examined incidences of hepatotoxicity, peripheral neuropathy, severe arthralgia, persistent vomiting and severe rash in 400 patients treated for tuberculosis in a community clinic. A total of 141 patients were co-infected with HIV, among whom only 16.3% were receiving antiretrovirals. Details of SAEs were ascertainable in 331/400 patients, and occurred in 26.7% of HIV-infected and 13.3% of HIV-uninfected individuals ( P = 0.003). The excess was attributable to increased peripheral neuropathy (8.3% and 1.9%, respectively, P = 0.009) and persistent vomiting (13.3% and 3.3%, P = 0.001). SAE occurrence was not related to antiretroviral use, although median CD4 counts were lower in those experiencing side-effects (130 and 259 cells/µL, P = 0.008). The treatment completion did not differ significantly between the two groups (76.6% and 84.2%, P = 0.08).Keywords
This publication has 24 references indexed in Scilit:
- Effectiveness of a Strategy to Improve Adherence to Tuberculosis Treatment in a Resource-Poor SettingJAMA, 2007
- International Standards for Tuberculosis CareThe Lancet Infectious Diseases, 2006
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaThe Lancet, 2006
- Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infectionThorax, 2006
- Diagnostic accuracy of an integrated respiratory guideline in identifying patients with respiratory symptoms requiring screening for pulmonary tuberculosis: a cross-sectional studyBMC Pulmonary Medicine, 2006
- Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis controlAIDS, 2006
- Global and regional burden of disease and risk factors, 2001: systematic analysis of population health dataThe Lancet, 2006
- Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatmentThe Lancet, 2006
- Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapyAIDS, 2002